CO6470845A2 - Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales - Google Patents
Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionalesInfo
- Publication number
- CO6470845A2 CO6470845A2 CO11165091A CO11165091A CO6470845A2 CO 6470845 A2 CO6470845 A2 CO 6470845A2 CO 11165091 A CO11165091 A CO 11165091A CO 11165091 A CO11165091 A CO 11165091A CO 6470845 A2 CO6470845 A2 CO 6470845A2
- Authority
- CO
- Colombia
- Prior art keywords
- cancer
- treatment
- pyrimidine derivatives
- additional diseases
- new pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención se refiere a compuestos de Fórmula (I):Donde L1, R1, R2, R3, R4 y X son como se los define en la descripción. La presente invención también se refiere a procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los contienen y su uso en el tratamiento de enfermedades, por ejemplo, cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18023809P | 2009-05-21 | 2009-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6470845A2 true CO6470845A2 (es) | 2012-06-29 |
Family
ID=42315702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11165091A CO6470845A2 (es) | 2009-05-21 | 2011-11-30 | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales |
Country Status (23)
Country | Link |
---|---|
US (2) | US20120122867A1 (es) |
EP (1) | EP2432768B1 (es) |
JP (1) | JP5913093B2 (es) |
KR (1) | KR20120030436A (es) |
CN (1) | CN102482233A (es) |
AR (1) | AR078045A1 (es) |
AU (1) | AU2010250923A1 (es) |
BR (1) | BRPI1010937A2 (es) |
CA (1) | CA2760766A1 (es) |
CL (1) | CL2011002942A1 (es) |
CO (1) | CO6470845A2 (es) |
CR (1) | CR20110610A (es) |
CU (1) | CU20110212A7 (es) |
DO (1) | DOP2011000361A (es) |
EA (1) | EA201101650A1 (es) |
EC (1) | ECSP11011470A (es) |
IL (1) | IL216283A0 (es) |
MX (1) | MX2011012337A (es) |
SG (1) | SG175796A1 (es) |
TW (1) | TW201100083A (es) |
UY (1) | UY32648A (es) |
WO (1) | WO2010133885A1 (es) |
ZA (1) | ZA201109384B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2491035T3 (pl) | 2009-10-22 | 2018-01-31 | Gilead Sciences Inc | Pochodne puryny lub deazapuryny przydatne do leczenia (między innymi) infekcji wirusowych |
WO2012067268A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
WO2012066335A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2012067269A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ[4,5−c]キノリン−1−イル誘導体 |
WO2012080730A1 (en) | 2010-12-17 | 2012-06-21 | Astrazeneca Ab | Purine derivatives |
EP2663367A4 (en) | 2011-01-10 | 2014-08-06 | Cleveland Biolabs Inc | USE OF A TOLL-TYPE RECEPTOR AGONIST FOR THE TREATMENT OF CANCER |
LT2694484T (lt) | 2011-04-08 | 2018-10-10 | Janssen Sciences Ireland Uc | Pirimidino dariniai, skirti virusinių infekcijų gydymui |
RS57851B1 (sr) | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Purinski derivati za tretman viralnih infekcija |
FR2985256B1 (fr) * | 2011-12-30 | 2016-03-04 | Pitty Marc Henry | Derives piperazinyles pour le traitement de cancers |
ES2716811T3 (es) * | 2012-02-08 | 2019-06-17 | Janssen Sciences Ireland Unlimited Co | Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas |
ES2644702T3 (es) * | 2012-05-18 | 2017-11-30 | Sumitomo Dainippon Pharma Co., Ltd. | Compuestos de ácido carboxílico |
ES2590508T3 (es) | 2012-07-13 | 2016-11-22 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para el tratamiento de infecciones víricas |
JP6283033B2 (ja) | 2012-10-05 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体 |
CN104837840B (zh) | 2012-10-10 | 2017-08-08 | 爱尔兰詹森科学公司 | 用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物 |
EA035431B1 (ru) | 2012-11-16 | 2020-06-15 | Янссен Сайенсиз Айрлэнд Юси | Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций |
AU2014220717B2 (en) * | 2013-02-21 | 2018-03-29 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
HUE031908T2 (en) | 2013-03-29 | 2017-08-28 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
US10377738B2 (en) | 2013-05-24 | 2019-08-13 | Janssen Sciences Ireland Unlimited Company | Pyridone derivatives for the treatment of viral infections and further diseases |
DK3030563T3 (da) | 2013-06-27 | 2017-11-20 | Janssen Sciences Ireland Uc | Pyrrolo-[3,2-d]-pyrimidin-derivater til behandling af virale infektioner og andre sygdomme |
MY179503A (en) | 2013-07-30 | 2020-11-09 | Janssen Sciences Ireland Uc | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
MX2017001279A (es) | 2014-07-30 | 2017-08-07 | Cleveland Biolabs Inc | Usos y composiciones de la flagelina. |
MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
EP3206708B1 (en) | 2014-10-16 | 2022-11-02 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
MY194902A (en) * | 2015-10-07 | 2022-12-22 | Sumitomo Pharma Co Ltd | Pyrimidine compound |
JP7171444B2 (ja) | 2016-07-01 | 2022-11-15 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染治療用のジヒドロピラノピリミジン |
EP3519406B1 (en) | 2016-09-29 | 2022-02-23 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
ES2906439T3 (es) | 2016-12-05 | 2022-04-18 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
CN110650729A (zh) | 2017-03-29 | 2020-01-03 | 大日本住友制药株式会社 | 疫苗佐剂制剂 |
WO2019124500A1 (ja) | 2017-12-21 | 2019-06-27 | 大日本住友製薬株式会社 | Tlr7アゴニストを含む併用薬 |
RU2020131012A (ru) * | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
WO2019236496A1 (en) | 2018-06-04 | 2019-12-12 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
US20210353737A1 (en) | 2018-07-23 | 2021-11-18 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
JP2023536945A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1375162A (es) | 1970-10-22 | 1974-11-27 | ||
GB1546937A (en) | 1976-07-29 | 1979-05-31 | Beecham Group Ltd | 2,4-diaminopyrimidine derivatives |
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
US5736549A (en) | 1994-10-05 | 1998-04-07 | Chiroscience Limited | Hypoxanthine and guanine compounds |
CA2230808C (en) | 1996-07-03 | 2006-08-15 | Japan Energy Corporation | A novel purine derivative |
EP1035123B1 (en) | 1997-11-28 | 2003-08-20 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
AU3213799A (en) * | 1998-04-01 | 1999-10-18 | Du Pont Pharmaceuticals Company | Integrin antagonists |
CA2341707C (en) * | 1998-08-27 | 2010-02-16 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidine derivatives |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
WO2001007027A2 (en) | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
CN1250548C (zh) | 2001-04-17 | 2006-04-12 | 大日本住友制药株式会社 | 新的腺嘌呤衍生物 |
CA2468011C (en) * | 2001-11-22 | 2012-04-10 | Japan Science And Technology Agency | Nonhuman model animal unresponsive to immunopotentiating synthetic compound |
US7115373B2 (en) | 2002-06-27 | 2006-10-03 | Genox Research, Inc. | Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene |
US7754728B2 (en) | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
WO2005007672A2 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (tlr) antagonists |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
JPWO2005092892A1 (ja) | 2004-03-26 | 2008-02-14 | 大日本住友製薬株式会社 | 8−オキソアデニン化合物 |
NZ549903A (en) | 2004-03-26 | 2010-04-30 | Astrazeneca Ab | 9-substituted 8-oxoadenine compound |
KR100700676B1 (ko) | 2005-06-24 | 2007-03-28 | (주) 비엔씨바이오팜 | 6―(4―치환된―아닐리노)피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
EP1931642A4 (en) | 2005-09-15 | 2011-06-01 | Orchid Res Lab Ltd | NEW PYRIMIDINE CARBOXAMIDES |
EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
UY30444A1 (es) | 2006-06-30 | 2008-01-31 | Astrazeneca Ab | Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos. |
CL2007002231A1 (es) | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
PE20081887A1 (es) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
ES2452965T3 (es) | 2007-09-05 | 2014-04-03 | Rigel Pharmaceuticals, Inc. | Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
-
2010
- 2010-05-20 UY UY0001032648A patent/UY32648A/es not_active Application Discontinuation
- 2010-05-20 AU AU2010250923A patent/AU2010250923A1/en not_active Abandoned
- 2010-05-20 WO PCT/GB2010/050825 patent/WO2010133885A1/en active Application Filing
- 2010-05-20 SG SG2011078433A patent/SG175796A1/en unknown
- 2010-05-20 EA EA201101650A patent/EA201101650A1/ru unknown
- 2010-05-20 CN CN2010800338249A patent/CN102482233A/zh active Pending
- 2010-05-20 JP JP2012511356A patent/JP5913093B2/ja active Active
- 2010-05-20 US US13/321,407 patent/US20120122867A1/en not_active Abandoned
- 2010-05-20 KR KR1020117030498A patent/KR20120030436A/ko not_active Application Discontinuation
- 2010-05-20 CA CA2760766A patent/CA2760766A1/en not_active Abandoned
- 2010-05-20 BR BRPI1010937A patent/BRPI1010937A2/pt not_active IP Right Cessation
- 2010-05-20 EP EP10721195.5A patent/EP2432768B1/en active Active
- 2010-05-20 MX MX2011012337A patent/MX2011012337A/es not_active Application Discontinuation
- 2010-05-21 AR ARP100101776A patent/AR078045A1/es unknown
- 2010-05-21 TW TW099116416A patent/TW201100083A/zh unknown
-
2011
- 2011-11-10 IL IL216283A patent/IL216283A0/en unknown
- 2011-11-21 CL CL2011002942A patent/CL2011002942A1/es unknown
- 2011-11-21 EC EC2011011470A patent/ECSP11011470A/es unknown
- 2011-11-21 CR CR20110610A patent/CR20110610A/es unknown
- 2011-11-21 DO DO2011000361A patent/DOP2011000361A/es unknown
- 2011-11-21 CU CU20110212A patent/CU20110212A7/es unknown
- 2011-11-30 CO CO11165091A patent/CO6470845A2/es not_active Application Discontinuation
- 2011-12-20 ZA ZA2011/09384A patent/ZA201109384B/en unknown
-
2014
- 2014-08-26 US US14/469,515 patent/US9533978B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2010250923A1 (en) | 2011-11-17 |
US9533978B2 (en) | 2017-01-03 |
JP2012527443A (ja) | 2012-11-08 |
ZA201109384B (en) | 2012-09-26 |
TW201100083A (en) | 2011-01-01 |
WO2010133885A1 (en) | 2010-11-25 |
EP2432768B1 (en) | 2017-07-05 |
US20120122867A1 (en) | 2012-05-17 |
UY32648A (es) | 2010-12-31 |
BRPI1010937A2 (pt) | 2019-09-24 |
CN102482233A (zh) | 2012-05-30 |
US20150080396A1 (en) | 2015-03-19 |
IL216283A0 (en) | 2012-01-31 |
DOP2011000361A (es) | 2011-12-15 |
KR20120030436A (ko) | 2012-03-28 |
CL2011002942A1 (es) | 2012-04-13 |
EP2432768A1 (en) | 2012-03-28 |
CA2760766A1 (en) | 2010-11-25 |
CR20110610A (es) | 2012-01-09 |
CU20110212A7 (es) | 2012-03-15 |
AR078045A1 (es) | 2011-10-12 |
JP5913093B2 (ja) | 2016-04-27 |
SG175796A1 (en) | 2011-12-29 |
ECSP11011470A (es) | 2011-12-30 |
MX2011012337A (es) | 2011-12-08 |
EA201101650A1 (ru) | 2012-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY31183A1 (es) | Derivados de pirazinona y procesos para su preparación | |
CR20120264A (es) | Compuestos | |
UY29803A1 (es) | Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
CO6270324A2 (es) | Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis | |
SV2011003855A (es) | Heteroarilos sustituidos | |
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
UY30789A1 (es) | Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
ECSP14013215A (es) | Compuestos novedosos | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
UY32673A (es) | Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos | |
CR20150171A (es) | Benzamidas | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
CL2010001432A1 (es) | Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas. | |
CO6460762A2 (es) | 5-alquinil-piridinas | |
UY32747A (es) | 2-carboxamida-cicloamino-ureas sustituidas | |
ECSP11011464A (es) | Tia-triaza-ciclopentazulenos | |
NI201200103A (es) | NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |